Thermo Fisher Scientific CD366 (TIM3) Monoclonal Antibody (RMT3-23), eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

1 µg/test

View 28 publications 28 publications

Neutralization (Neu)

-

View 1 publication 1 publication

Functional Assay (Functional)

-

View 4 publications 4 publications

Product Specifications

Published species

Human, Mouse

Host/Isotype

Rat / IgG2a, kappa

Class

Monoclonal

Type

Antibody

Clone

RMT3-23

Conjugate

Unconjugated Unconjugated Unconjugated

View additional formats

• APC
• Brilliant Violet 421
• Brilliant Violet 605
• Brilliant Violet 650
• Brilliant Violet 711
• FITC
• PE
• PE-Cyanine7
• PerCP-eFluor 710
• Super Bright 436
• Super Bright 702
• Request custom conjugation

Form

Liquid

Concentration

0.5 mg/mL

Storage conditions

4° C

Shipping conditions

Wet ice

RRID

AB_467643

Product Specific Information

Description: The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4^+Th1 and CD8^+Tc1 cells, but is absent on CD4^+Th2 and CD8^+Tc2 cells. Other hematopoietic cell types, including naive T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4^+ and CD8^+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4^+ cells in the periphery expressed CD366 after immunization.

RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production.

Applications Reported: This RMT3-23 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This RMT3-23 antibody has been tested by flow cytometric analysis of CD366 transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

TIM3 (Hepatitis A virus cellular receptor 2, HAVCR2, T-cell immunoglobulin, mucin-dmain containing-3) is a 281 amino acid long, Type-1 Th1- specific cell surface glycoprotein expressed on terminally differentiated CD4+Th1 and CD8+Tc1 cells. TIM3 consists of an IgV-like domain, a mucin-like domain in the extracellular region, and a conserved Tyrosine phosphorylation motif in the cytoplasmic region. TIM3 is involved in macrophage activation and induction of autoimmune diseases. Further, TIM3 down-regulates aggressive Th1-mediated immune responses and facilitates in the development of immune tolerance. Pathological significance of TIM3 has been attributed to Experimental autoimmune encephalomyelitis (EAE), a Th-1 dependent autoimmune disease, and also enhances the severity of experimental autoimmune encephalomyelitis in mice.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.